Intellia Therapeutics/$NTLA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Intellia Therapeutics
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
- Ticker
- $NTLA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 377
- Headquarters
- Cambridge, United States
- Website
- www.intelliatx.com
NTLA Metrics
BasicAdvanced
$1.7B
-
-$3.34
1.82
-
Price and volume
Market cap
$1.7B
Beta
1.82
52-week high
$18.48
52-week low
$7.95
Average daily volume
5.2M
Financial strength
Current ratio
6.648
Quick ratio
5.606
Long term debt to equity
0.069
Total debt to equity
0.101
Profitability
EBITDA (TTM)
-414.4
Gross margin (TTM)
-374.44%
Net profit margin (TTM)
-672.16%
Operating margin (TTM)
-711.66%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-30.14%
Return on equity (TTM)
-55.44%
Valuation
Price to revenue (TTM)
25.062
Price to book
2.4
Price to tangible book (TTM)
2.4
Price to free cash flow (TTM)
-4.277
Free cash flow yield (TTM)
-23.38%
Free cash flow per share (TTM)
-2.916
Growth
Revenue change (TTM)
12.58%
Earnings per share change (TTM)
-28.59%
3-year revenue growth (CAGR)
3.91%
10-year revenue growth (CAGR)
20.31%
3-year earnings per share growth (CAGR)
-14.98%
10-year earnings per share growth (CAGR)
-3.01%
What the Analysts think about NTLA
Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.
Analyst projections of the future price of Intellia Therapeutics stock.
Bulls say / Bears say
In Phase 3, a one-off lonvo-z infusion cut hereditary angioedema attacks by 87% versus placebo; 62% of treated patients were attack-free and off preventive therapy during the six-month assessment, against 11% on placebo. This strong result supports the treatment’s potential to offer a major improvement for patients. (Intellia Therapeutics)
The FDA accepted lonvo-z’s application for priority review, set 10 March 2027 as its target decision date and is not currently planning an advisory committee meeting. That gives Intellia a clear near-term regulatory milestone for a possible first-in-class in vivo CRISPR treatment. (SEC)
Intellia reported $628.4 million in cash, equivalents and marketable securities at the end of June, which it expects to fund operations into at least 2028, beyond lonvo-z’s planned US launch. The company says this runway estimate excludes any potential product revenue. (Intellia Therapeutics)
Nex-z’s Phase 3 programme has faced a serious safety setback: a patient developed severe liver toxicity and died, prompting clinical holds and tighter monitoring requirements. The FDA has allowed trials to resume, but the event highlights a material risk to the programme’s safety profile and progress. (BioSpace, Oligonucleotide Therapeutics Society)
Intellia has linked the largest liver-enzyme rises in nex-z patients to a particular HLA allele, and is still discussing the findings with regulators while introducing genotyping in its trials. The safety-management approach is therefore still developing, leaving uncertainty around the ATTR programme. (BioSpace)
Commercial uptake may be harder than the clinical data alone suggest: Barclays argues that existing drugs already serve the HAE and ATTR markets well, and that high-cost treatments have historically been slow to gain traction. That could limit sales expectations for Intellia’s prospective products. (Business Insider)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
NTLA Financial Performance
Revenues and expenses
NTLA Earnings Performance
Company profitability
Upcoming events
No upcoming events
NTLA News
AllArticlesVideos
Funds containing NTLA
Fund name | Fund size | $NTLA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.12% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.06% |
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.